Market Snapshot
S&P Futures
3,914.75
Dow Futures
31,478
Nasdaq Futures
12,132.75
Gritstone bio, Inc. (GRTS) stock rallied over 5.14% intraday to trade at $2.66 a share on NASDAQ. The stock opened with a gain of 14.16% at $2.53 and touched an intraday high of $2.66, rising 5.14% against the last close of $2.53. The stock went to a low of $2.44 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-23 | $2.53 | $2.66 | $2.44 | $2.66 | 1,044,400 |
2022-06-22 | $2.33 | $2.64 | $2.29 | $2.53 | 1,396,500 |
2022-06-21 | $2.29 | $2.42 | $2.25 | $2.38 | 1,040,500 |
2022-06-17 | $2.11 | $2.33 | $2.09 | $2.22 | 1,729,400 |
2022-06-16 | $2.11 | $2.17 | $2.02 | $2.13 | 1,212,700 |
2022-06-15 | $2.14 | $2.24 | $2.09 | $2.19 | 854,500 |
2022-06-14 | $2.15 | $2.15 | $2.04 | $2.1 | 877,800 |
2022-06-13 | $2.22 | $2.22 | $2.03 | $2.08 | 1,035,300 |
2022-06-10 | $2.25 | $2.33 | $2.19 | $2.25 | 1,548,000 |
2022-06-09 | $2.31 | $2.35 | $2.24 | $2.26 | 1,821,700 |
Employees-
Beta0.6
Sales or Revenue48.21 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Gritstone bio, Inc. (NASDAQ: GRTS) stock price is $2.66 as of the last check on Thursday, June 23. During the trading session, GRTS stock reached the peak price of $2.66 while $2.44 was the lowest point it dropped to.
The NASDAQ listed GRTS is part of Biotechnology industry that operates in the broader Health Care sector. Gritstone bio, Inc. , a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases.
Mr. Erin E. Jones M.S.
Chief Operating Officer
Dr. Karin Jooss
Head of R&D
Mr. Alan C. Mendelson J.D.
Sec.
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Co-Founder, Pres, CEO & Director
GRTS stock traded closed the last session at $2.66, which is $0.13 or 5.14% lower than its previous close of $2.53. GRTS's current trading price is 55.56% lower than its 52-week high of $14.42 where as its distance from 52-week low of 1.71% is -81.55%.
Number of GRTS employees currently stands at -. GRTS operates from 5959 Horton Street, Suite 300, EmeryVille, CA 94608, United States.
Official Webiste of $GRTS is: https://gritstonebio.com
GRTS could be contacted at GRTS operates from 5959 Horton Street, Suite 300, EmeryVille, CA 94608, United States, or at phone #510 871 6100 and can also be accessed through its website.
GRTS stock volume for the day was 1,043,836 shares while in the previous session number of GRTS shares traded was 1,044,400 . The average number of GRTS shares traded daily for last 3 months was 1.2 Million.
The percentage change in GRTS stock occurred in the recent session was 5.14% while the dollar amount for the price change in GRTS stock was $0.13.
In the recent session, the day high for GRTS stock was $2.66 while the low for GRTS stock touched on the day was $2.44.
The market value of GRTS currently stands at 185.83 Million with its latest stock price at $2.66 and 86.28 Million of its shares outstanding.